Aurobindo Pharma announced that the USFDA has issued a warning letter for Unit-III of Eugia Pharma Specialities, a subsidiary of the company. There is no impact on the existing supplies to the US market.
The warning letter comes subsequent to receiving the Official Action Indicated (OAI) status from USFDA earlier in May 2024.
History of Stock Market Crashes
8 mins read . Oct 17, 2024
History of ITC Group
10 mins read . Oct 16, 2024
Public Sector Undertakings in India
9 mins read . Oct 11, 2024
